The Ozempic Effect: 35% of US Food and Beverage Sales Will Come from GLP-1 Users by 2030 — Who's Winning and Who's Not

📊 Analytics & Strategic Insight

GLP-1 Adoption Is Not a Health Trend — It Is a Demand Architecture Shift, and Most Food Portfolios Are Not Built for It

The decision most in this industry are avoiding:

👉 Most operators are treating GLP-1 as a consumer trend to monitor, not a structural event to act on. That is a category mistake. When 35% of US food and beverage units will flow through GLP-1 households by 2030, the question is not whether to respond — it is whether there is still time to build the right portfolio before acquisition premiums make it prohibitively expensive.

👉 The biggest risk is not in the snacking aisle — it is in the mid-tier, mid-calorie mass market. Premium formats and functional categories will attract GLP-1 users who still indulge selectively. Value formats will hold through price sensitivity. The squeeze is in the undifferentiated middle: standard calorie-dense, brand-name snacks that can't justify a price premium and don't offer a functional reason to stay in the basket.

👉 Pharma is setting product design briefs that food R&D teams have not been asked to meet. GLP-1 users need protein to preserve muscle mass, fibre to manage satiety, and electrolytes to manage hydration as the drugs suppress fluid intake alongside caloric intake. The companies that embed these formulation priorities into mainstream SKUs — not just specialty lines — will be the ones with volume staying in the category.

Here's the full context:

→ 2023–2024: GLP-1 prescription volumes surged. Novo Nordisk and Eli Lilly reported supply shortages as demand for Ozempic and Wegovy exceeded production capacity. Food analysts initially treated this as a healthcare story with limited CPG implications.

→ 2024: Circana and McKinsey began tracking basket data for GLP-1 households. Results showed savory snack spending down approximately 10%, confectionery and bakery contracting, and protein and functional beverage formats outperforming. The category shift became visible in retail data.

→ Early 2026: An estimated 1 in 8 US adults is on a GLP-1 drug. By 2030, GLP-1 households are projected to represent 35% of all US food and beverage units sold, according to Food Dive citing industry research. The global GLP-1-friendly hydration segment alone is forecast at USD 3.48 billion by 2033.

→ April–May 2026: Q1 earnings season surfaces the divergence in real numbers. Hershey posts 17% protein bar growth, 8% Ice Breakers growth, and 5% organic volume growth in clean-label salty snacks. Mondelez absorbs a USD 500 million cocoa cost headwind while betting on premiumisation. General Mills cuts its full-year sales outlook while prioritising protein-forward innovation.

→ Most recent: Hershey specifically attributed Ice Breakers mint growth to "Ozempic breath" — a documented GLP-1 side effect — on its Q1 2026 earnings call (April 30, 2026). This is the first time a major food company has disclosed a named GLP-1 side effect as a direct revenue driver, signalling how deep the pharmaceutical-consumer link now runs in category behaviour.

What this means for food and beverage operators and investors:

✅ Portfolio exposure to GLP-1 risk should now be part of every investment thesis and asset review. Any business generating more than 40% of revenue from conventional snacking, standard confectionery, or high-calorie mainstream formats faces a structural demand headwind over the 2026–2030 horizon that will not be reversed by marketing investment alone.

✅ The acquisition window for GLP-1-aligned assets is narrowing fast. Protein bars, clean-label popcorn, functional hydration, electrolyte beverages, and premium small-portion formats are all attracting strategic buyers at elevated multiples. Celsius-Alani Nu at USD 1.8 billion, Hershey-LesserEvil, and the broader functional beverage M&A wave are compressing available targets. The second-tier opportunities will be acquired in 2026–2027.

✅ Reformulation is not enough — distribution and brand architecture need to follow. Adding protein to an existing SKU in a confectionery brand does not solve the positioning problem for GLP-1 users who are actively seeking foods designed for their new nutritional needs. Category entry through standalone brands or acquisitions is likely to be more effective than reformulation of legacy lines.

3 moves you can make this week:

1️⃣ Run a GLP-1 exposure audit on your portfolio or acquisition target. Map revenue by category and identify what percentage of sales flows from formats likely to be structural losers (mid-calorie confectionery, standard snack packs, full-sugar beverages) versus structural winners (protein, functional hydration, clean-label, premium small-portion). This single exercise will clarify where strategic investment is needed and where divestiture should be considered.

2️⃣ Track the prescription penetration curve in your key markets. GLP-1 adoption in Europe is running approximately 18–24 months behind the US curve. European food operators have a window — closing now — to reposition ahead of the demand shift rather than in reaction to it. Regulatory approvals for Wegovy in major EU markets are already in place; the limiting factor is reimbursement, which is expanding.

3️⃣ Stress-test your 2027–2030 volume forecasts against a 35% GLP-1 household penetration scenario. Most food company financial models are not yet incorporating this. The companies whose boards are running this scenario now will make better capital allocation decisions on innovation, M&A, and divestiture than those running models built on pre-2023 consumer behaviour assumptions.